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The treatment of autoimmune rheumatic diseases has gradually improved over the last
half  century, which has been expanded with the contribution of biological therapies or
immunobiopharmaceuticals. However, we must be alert to the possibilities of undesirablevailable online 27 November 2014 effects from the use of this class of medications. The Brazilian Society of Rheumatology
(Sociedade Brasileira de Reumatologia) produced a document based on a comprehensive
literature review on the safety aspects of this class of drugs, speciﬁcally with regard to the
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treatment of rheumatoid arthritis and spondyloarthritides. The themes selected by the
participating experts, on which considerations have been established as the safe use of
biological drugs, were: occurrence of infections (bacterial, viral, tuberculosis), infusion reac-
tions,  hematological, neurological, gastrointestinal and cardiovascular reactions, neoplastic
events (solid tumors and hematologic neoplasms), immunogenicity, other occurrences and
vaccine response. For didactic reasons, we opted by elaborating a summary of safety assess-
ment in accordance with the previous themes, by drug class/mechanism of action (tumor
necrosis factor antagonists, T-cell co-stimulation blockers, B-cell depletors and interleukin-
6  receptor blockers). Separately, general considerations on safety in the use of biologicals in
pregnancy and lactation were proposed. This review seeks to provide a broad and balanced
update of that clinical and experimental experience pooled over the last two decades of use
of  immunobiological drugs for RA and spondyloarthritides treatment.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Seguranc¸a
r  e  s  u  m  o
O tratamento das doenc¸as reumáticas autoimunes sofreu uma progressiva melhora ao
longo da última metade do século passado, que foi expandida com a contribuic¸ão das ter-
apias biológicas ou imunobiológicos. No entanto, há que se atentar para as possibilidades
de  efeitos indesejáveis advindos da utilizac¸ão dessa classe de medicac¸ões. A Sociedade
Brasileira de Reumatologia (SBR) elaborou um documento, baseado em ampla revisão da
literatura, sobre os aspectos relativos à seguranc¸a dessa classe de fármacos, mais especiﬁca-
mente no que diz respeito ao tratamento da artrite reumatoide (AR) e das espondiloartrites.
Os  temas selecionados pelos especialistas participantes, sobre os quais foram estabele-
cidas considerac¸ões quanto à seguranc¸a do uso de drogas biológicas, foram: ocorrência
de  infecc¸ões (bacterianas, virais, tuberculose), reac¸ões infusionais, reac¸ões hematológicas,
neurológicas, gastrointestinais, cardiovasculares, ocorrências neoplásicas (neoplasias sóli-
das  e da linhagem hematológica), imunogenicidade, outras ocorrências e reposta vacinal.
Optou-se, por motivos didáticos, por se fazer um resumo da avaliac¸ão de seguranc¸a, de
acordo com os tópicos anteriores, por classe de drogas/mecanismo de ac¸ão (antagonistas
do  fator de necrose tumoral, bloqueador da co-estimulac¸ão do linfócito T, depletor de linfóc-
ito  B e bloqueador do receptor de interleucina-6). Em separado, foram tecidas considerac¸ões
gerais sobre seguranc¸a do uso de biológicos na gravidez e na lactac¸ão. Esta revisão procura
oferecer uma atualizac¸ão ampla e equilibrada das experiências clínica e experimental
acumuladas nas últimas duas décadas de uso de medicamentos imunobiológicos para o
tratamento da AR e espondiloartrites.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The treatment of autoimmune rheumatic diseases has
gradually improved over the last half century, and has
been expanded with the contribution of biological or
immunobiological therapy (also called biological agents or
disease-modifying drugs – DMD-biologicals). This entire pro-
cess has been implicated in improving therapeutic outcomes
and the quality of life, as well as in reducing the morbidity and
mortality of patients.1,2
Concomitantly, there has been a proportional strengthen-
ing of Rheumatology as a medical specialty. Such a scenario
is very favorable and signals an auspicious perspective for
individuals suffering from autoimmune rheumatic diseases.
Monoclonal antibodies and recombinant molecules (or fusionproteins), able to interfere with the signaling of cellular
processes, multiply in a fast pace, and new therapeutic possi-
bilities will be progressively added.3–5
However, as with any drug class, we  must be alert to the
possibility of undesirable effects from the use of immuno-
biological medicines – an aspect which becomes even more
important, given the intense action of these molecules on vari-
ous immunological processes of critical importance. Added to
this is the fact that many  of the targets of these molecules
participate in multiple physiological processes, extending the
range of possible effects of the respective inhibitors or antag-
onist drugs.Security issues are important for the patient to attain
a position of maximum possible well-being; such questions
guide medical treatment since ancient times. With respect
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o the use of immunobiological agents used in Rheumato-
ogy, the application of this premise can help in choosing the
est option for each patient. With the advent of new thera-
ies, the main questions from patients and physicians focus
ot only on the beneﬁts and costs, but also on the safety of
hese medications. Thus, in addition to considering the mech-
nism of action and pharmacological peculiarities of each
gent, including dosage, plasma and biological half-life and
oute of administration, as well as the opinion, adherence and
he degree of understanding of the patient, the rheumatolo-
ist must weigh the major adverse events for each particular
cenario.6
With these considerations in mind, the Brazilian Soci-
ty of Rheumatology (Sociedade Brasileira de Reumatologia/SBR)
eemed appropriate to elaborate a text on the safety aspects of
his class of drugs. This document represents the consensus of
he members of the Commission on Rheumatoid Arthritis (RA)
f SBR and of several invited experts, including members of the
BR’s Commission on Spondyloarthritides and other rheuma-
ologists who attended the IV Forum on Biological Agents –
ocus on Safety, sponsored by SBR.
bjective
he aim of this study was to provide a document representing
he opinion of experts, based on extensive literature review on
spects relating to the safe use of immunobiological drugs in
heumatology, speciﬁcally with regard to the treatment of RA
nd spondyloarthritides.
ethod
he method of elaboration of this paper included a litera-
ure review, conducted by rheumatology experts, members
f the Commission on RA of SBR and other invited experts,
embers of the Commission on Spondyloarthritides of SBR
nd participants of IV Forum on Biological Agents – Focus on
ecurity, held on July 20/21, 2012, in São Paulo, Brazil. The bib-
iographical survey covered existing publications in MEDLINE,
ciELO, PubMed and EMBASE up to February 2013. Recom-
endations were written and re-evaluated by all participants
uring multiple rounds of questioning and corrections made
ia the Internet.
The themes selected by the participating experts, about
onsiderations given regarding the safety of the use of
iological drugs in rheumatology, were: occurrence of
nfections (bacterial, viral, tuberculosis), infusion reactions,
ematological, neurological, gastrointestinal and cardio-
ascular reactions, neoplastic events (solid tumors and
ematological lineage neoplasms), immunogenicity, other
ccurrences and vaccine response. For didactic reasons,
e opted by elaborating a summary of the safety assess-
ent, in accordance with the previous themes, by drug
lass/mechanism of action and, separately, general consider-
tions on safety in the use of biologicals in pregnancy and
actation. 5;5 5(3):281–309 283
Safety  assessment  by  drug  class/mechanism  of  action
Tumor  necrosis  factor  antagonists  (anti-TNF)
Tumor necrosis factor alpha (TNF) is a proinﬂammatory
cytokine that exerts multiple effects on different cell types
and plays a critical role in the pathogenesis of chronic inﬂam-
matory diseases, such as RA, ankylosing spondylitis (AS),
psoriatic arthritis (PA), and arthritis associated with inﬂam-
matory bowel diseases (enteropathic arthritis).7 TNF exerts
cytotoxic action on different types of lymphocytes, stimulat-
ing their apoptosis and that of endothelial cells. Currently,
there are ﬁve different anti-TNF biological agents (also called
TNF blockers) marketed: adalimumab (ADA), a 100% human
monoclonal antibody; certolizumab (CERT) pegol, a Fab frag-
ment of a humanized anti-TNF antibody with high afﬁnity for
TNF, conjugated with two molecules of polyethylene glycol
(5–10% of animal protein); etanercept (ETN), a fusion pro-
tein composed of TNF soluble receptor plus Fc region of IgG;
golimumab (GOL), another human monoclonal antibody; and
inﬂiximab (IFX), a chimeric monoclonal antibody (25–30% of
animal protein).8 With the exception of IFX, a drug for intra-
venous (IV) use, the biological agents of anti-TNF class are
drugs for subcutaneous (SC) use.
The biological agents of the anti-TNF class are prescribed
where there is no response, or only an incomplete (par-
tial) response was obtained, to basic conventional drugs,
mainly methotrexate (MTX), both in RA9,10 and PA.11,12 On
the other hand, in AS patients these biologicals may be pre-
scribed after failure with continuous use of non-steroidal
anti-inﬂammatory drugs (NSAIDs), in cases of predominantly
axial disease, and after basic conventional drugs, in cases of
peripheral disease.13,14
Used in the treatment of RA for almost two  decades, anti-
TNF agents usually are used for at least ﬁve years in 60% of the
patients, according to the Dutch Rheumatoid Arthritis Moni-
toring register.15 Its use for over a decade has not presented
serious risks with respect to long-term safety in RA.16 The
possibility of successive exchanges of biological agents in the
long-term follow-up of patients with RA can bring questions
about to what agent to impute beneﬁcial or adverse effects.17
On the other hand, anti-TNF agents represent the only class
of biological agents currently in proven use in AS. There are
records of good response maintained in face of the use of IFX
for eight years,18 ETN for four years,19 ADA for ﬁve years20 and
GOL for two  years.21 There is no difference in efﬁcacy among
the various anti-TNF drugs in the treatment of AS. The sud-
den discontinuation of IFX, after a good sustained response
for three years, led to relapse in more  than 90% of the patients
within a 1-year period.22 While anti-TNF maintenance is simi-
lar in AS and RA after one year of follow-up, the persistent use
of anti-TNF in the long term is signiﬁcantly longer in patients
with AS.23 Also in PA, anti-TNF agents maintain good response
to treatment over time, with no deadline for discontinuation
of these drugs.24–26
Anti-TNF medications are contraindicated in pregnant or
breastfeeding women, in patients with congestive heart fail-
ure (CHF) classes III and IV according to the New York Heart
Association (NYHA), in the presence of active infection or
at high risk for development of infections (chronic ulcer of
 o l . 2284  r e v b r a s r e u m a t
lower limbs, septic arthritis in the past 12 months), recurrent
pulmonary infections, multiple sclerosis, and with current
or previous diagnosis of neoplasia (less than ﬁve years). The
patient should be carefully monitored, with assessment of
possible emergence of signs of infection, that should be
treated promptly and immediately.7–9
Infections
In the maintenance of any anti-TNF agent, both at the begin-
ning of treatment and after years of medication, infection is
the most frequent and important adverse event. Generally,
these are usually bacterial or viral infections, mainly affect-
ing the respiratory tract, skin, soft tissues and urinary tract.27
The risk of hospitalization due to bacterial infection is twice as
high in patients using anti-TNF than in patients in monother-
apy with MTX; this risk increases four times when considering
the ﬁrst six months of treatment.28
Most available data on the risk of infection in patients on
biologic therapy concern the ﬁrst anti-TNF agents: IFX, ETN
and ADA. No deﬁnitive comparative studies were published.
Meta-analyses and observational study assessments showed
no signiﬁcant difference in the incidence of infectious com-
plications among different biological agents. Albeit with a
shorter observation time, the current understanding is that
the newer anti-TNF agents, e.g. GOL and CERT, are associated
with the same risk of infection.29
Although clinical trials have not shown signiﬁcant increase
versus placebo, meta-analyses, extension studies and post-
marketing registries conﬁrmed a higher risk of infection in
patients with rheumatic diseases using biological agents. The
relative risk (RR) for different forms of infection varies from
1.2 to 2.8 compared to synthetic or non-biological DMDs, e.g.
MTX.29,30 Severe infections – deﬁned as infections requiring
hospitalization and/or IV antibiotics – and opportunistic infec-
tions such as tuberculosis and Pneumocystis carinii and fungal
infections, also increased in patients on biologic therapy.31
The incidence of infectious complications do not increase with
the progression of treatment and appears to be greatest in the
ﬁrst months of exposure to biological agents.27,31
Variations in the spectrum of signs and symptoms asso-
ciated with infection and atypical clinical presentations are
common, and this requires a careful monitoring and clin-
ical suspicion for a correct diagnosis.30 Skin infections are
among the most common adverse effects with the use of
anti-TNF.29 They account for about 20% of all infectious com-
plications associated with TNF inhibitors, being second only
to respiratory tract involvement.30 Cellulitis of bacterial origin
and herpes zoster virus infections are among the most com-
mon cutaneous infectious complications. Although infection
by herpes zoster is more  common in RA patients than in the
general population, recent studies show an increased risk in
users of immunobiological therapy.32,33
As infectious complication, tuberculosis requires special
attention. Considering that TNF plays a central role in the for-
mation and maintenance of granuloma integrity, tuberculosis
34is an adverse event that should be potentially very frequent,
had it not been its systematic prevention, which should never
be neglected. Most cases occur in the ﬁrst months of treat-
ment with anti-TNF and the frequencies of extra-pulmonary 0 1 5;5 5(3):281–309
tuberculosis and atypical presentations are higher in patients
using anti-TNF agents.35
Observational studies and meta-analyses sought to eval-
uate differences in the risk of tuberculosis among different
anti-TNF agents, and the results are conﬂicting. The current
understanding is that, if there is a difference, this would not
be of clinical signiﬁcance.36 The risk of reactivation of tuber-
culosis appears to be lower with other biological agents, but
there are no deﬁnitive data. That is why a screening exam for
latent tuberculosis is in order, as well as its treatment in all
patients that will depend on the use of biological agents.
Like other specialty societies, SBR recommends a screening
for latent tuberculosis through epidemiology, chest imaging
and tuberculin skin test (PPD).37 When available, -interferon
release in vitro assays (IGRA – interferon gamma release assay),
e.g. Quantiferon® or Elispot®, can enhance the accuracy of
a latent tuberculosis diagnosis.38 Patients with evidence of
latent tuberculosis should receive isoniazid for six months.
During pregnancy there is a physiological state of immune
suppression, which is important for the mother’s relationship
with fetal allogenic immunogenicity. At this point, the levels of
progesterone increase, with consequent Th1 to Th2-response
shift. Quantiferon® test depends on the integrity of the cellu-
lar immune response of Th1, and thus the performance of this
test may be poorer during pregnancy. While possibly with clin-
ical importance, to date there are no tests available for use in
clinical practice allowing monitoring the onset and intensity
of antibodies against anti-TNF drugs and other biologicals.
Regarding the evaluation of Latent Tuberculosis Infection
(LTBI) in patients who are already in use of some TNF blocker,
the epidemiological investigation of contactants and/or re-
exposure to mycobacteria should be done actively at every
outpatient visit, in order to ensure an adequate surveillance of
new cases. In the presence of a positive epidemiology, includ-
ing personal, family and professional data, a revaluation of
LTBI is indicated.
In the case of PPD greater than or equal to 5 mm in patients
with no prior treatment of LTBI before the use of anti-TNF
agents, isoniazid must be initiated and maintained for six
months. There is no need to discontinue TNF antagonists
in asymptomatic patients. In those symptomatic patients, a
proper expert evaluation is critical.
Assuming the lack of consistent scientiﬁc data on the
necessity of repeating the tuberculin skin test (PPD), a booster
test (PPD-Booster) and chest radiography in this setting, we  do
not recommend the practice of routine and/or annual inves-
tigation in asymptomatic patients and/or in the absence of
convincing epidemiological data.
However, the rheumatologist may request a LTBI re-
investigation in doubtful cases of clinical management,
considering the local prevalence of tuberculosis, clinical data
(alcoholism and malnutrition and other conditions associated
with immunosuppression, for example) and socioeconomic
conditions. This topic will be discussed in more  detail in a
speciﬁc document on the management of endemic diseases
in patients with RA, now in production phase by SBR.In the presence of hepatitis B and C infection, the use of
anti-TNF should be avoided. In exceptional cases of hepati-
tis C virus infection, anti-TNF drugs can be used, with the
associated antiviral treatment.37
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The treatment of other infectious diseases, including
ndemic/epidemic diseases in Brazil, such as leprosy, malaria,
hagas disease, esquistosomiasis, leishmaniasis, ﬁlariasis,
engue, yellow fever, fungal infections (blastomycosis, para-
occidioidomycosis, etc.), among others, will be discussed in
 speciﬁc document by SBR.
nfusion  reactions
ost skin reactions related to the administration of TNF
nhibitors have mild to moderate intensity and do not require
iscontinuation of the drug.39 The most common reactions
re: erythema, urticaria, eczema or rash, which may, in turn,
e accompanied by pain or edema.39 While the appearance of
ash has been described in approximately 6.9% of the patients
n use of IFX,40 injection site reactions were reported in 40%
f the cases with ETN41 and in 15% of the cases with ADA.42
ith respect to the new anti-TNFs, the incidence of reactions
t the injection site appears to be lower: 2.3% with CERT43 and
.4% with GOL.44
ematological  reactions
hanges such as thrombocytopenia, anemia (aplastic type)
nd pancytopenia are rarely reported during anti-TNF therapy,
lthough some recommendations, such as the UK guidelines
nd the 2012 Consensus of the Brazilian Society of Rheuma-
ology on Treatment of Rheumatoid Arthritis, suggest blood
eries monitoring.37,45 To date, 19 cases of thrombocytopenia
ere described in the literature in association with anti-TNF.46
one of the cases was associated with signiﬁcant clinical con-
itions or major bleeding. Moreover, leukopenia is a blood
eries abnormality that may be seen a little more  commonly
n some patients under anti-TNF therapy.47 In this sense, a
tudy involving 130 patients using IFX reported leucopenia in
bout 12% of the cases.48 The possibility of marrow blockage
r peripheral lysis has been evaluated, and it is suggested that
his latter possibility is the most frequent.49
The occurrence of neutropenia is deﬁned as a neu-
rophil count below 1500/mm3 and the risk of infection is
ncreased with neutropenia <1000/mm3. So far, neutropenia
as reported in 111 patients using anti-TNF agents, most
f them diagnosed with RA, and 96% were not in treatment
ith other immunosuppressive medication with potential to
enerate neutropenia. Most cases were using ESV (72.8%), fol-
owed by IFX (18.5%) and ADA (9%). One study showed that
wo important risk factors are a neutrophil count <4000 mm3
efore the use of anti-TNF and a history of neutropenia due
o synthetic DMDs. The presence of severe events accompa-
ied by neutropenia has been reported in 6% of the cases, with
o deaths associated.46 Considering the data currently avail-
ble, the conclusion is that the use of anti-TNF seems to be
ssociated with lower risk of hematological changes, throm-
ocytopenia being a very rare event, and leucopenia due to
eutropenia being the most frequent manifestation. As a rou-
ine, a cell blood count could be useful immediately before
tarting and during follow-up of patients in use of immunobi-
logicals.eurological  reactions
o diagnose the neurological event associated with the use of
iologic therapy, the following phenomena should be taken
nto account: the causal link between the use and the event, 5;5 5(3):281–309 285
observation of partial or complete improvement after drug
withdrawal, relapse of symptoms after possible reintroduction
of the biological agent, evidence of neurological involvement
and, if possible, comparison with the expected incidence for
the population.50
Various neurological disorders have been described in
patients on biologic therapy. Among them are: onset or
exacerbation of multiple sclerosis, optic neuritis and var-
ious forms of demyelinating peripheral neuropathy. The
prevalence of demyelinating disease induced by the use of
biologicals, reported in randomized controlled trials and in
post-marketing studies on autoimmune diseases (RA, juvenile
idiopathic arthritis, spondyloarthritides and Crohn’s disease)
is estimated to be between 0.02% and 0.20%. A meta-analysis
of these studies showed a prevalence of 0.05–0.20%. The cases
are described mainly with the use of TNF blockers (IFX,
ETN and ADA) and with the greatest number of cases occur-
ring with monoclonal antibodies.51 The mean elapsed time
between the beginning of a biological DMD  and the onset of
symptoms was 7.5 months (range, 2–18 months) and with a
favorable outcome after drug discontinuation and treatment
in 66% of the cases.51
Demyelinating diseases of the central nervous sys-
tem (CNS) showed less favorable outcomes. Multifocal
leukoencephalopathy (MLE) exhibited greater correlation with
natalizumab (taken away from the market due to this event)
and, to a lesser extent, with alemtuzumab and alfalizumab,
all not approved for use in the treatment of RA.52 By the time
of preparation of this manuscript, MLE had been conﬁrmed in
a case of a patient diagnosed with RA in use of IFX.53
Guillain–Barré syndrome is also described in patients with
RA being treated with anti-TNFs and, as one of its causes, viral
infection prior to the event must be remembered, since the risk
of virus infection is increased when using these agents.54
Two studies which evaluated the use of anti-TNF for
multiple sclerosis treatment were discontinued due to exac-
erbation of the disease, suggesting the deleterious effect of
these agents for this condition.55,56 An analysis by Fernández-
Espartero et al., in Spain, comparing a systematic literature
review (SLR) of case reports in the medical literature with the
Spanish register of biological agents BIOBADASER (Spanish
Registry of Biological Therapies in Rheumatic Diseases) and
the pharmacosurveillance system of Spain, FEDRA (Spanish
Pharmacosurveillance Database of Adverse Drug Reactions)
failed to establish a clear association between the use of
anti-TNF (IFX, ETN and ADA) for the treatment of rheumatic
disorders and the occurrence of demyelinating disease.57
Data from BIOBADASER, with an exposition of
13,075 patients/year with a diagnosis of RA, conﬁrmed nine
cases of demyelinating disease (22 suspected, unconﬁrmed,
cases), with an incidence rate of 0.69 per 1000 patient-years
(95% CI: 0.36–1.32). The incidence of multiple sclerosis in
the Spanish population (0.022–0.038) was similar to the rate
observed in patients who received anti-TNF (0.01–0.33).57 Data
from FEDRA described 10 cases of demyelinating diseases
in RA patients treated with anti-TNF, and SLR found 31 case
reports. The more  frequent types of demyelination were: mul-
tiple sclerosis, optic neuritis and peripheral demyelinating
disease. Among the rheumatic diseases studied, RA accounted
for over 50% of the cases in the three analyses, with similar
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distribution between gender and age and with an incidence
rate lower than in PA (1.04/1000, 95% CI: 0,34–3.24) and AS
(0.70/1000, 95% CI: 0.17–2.79). In BIOBADASER register, a longer
time of anti-TNF exposition (mean, 1.44 years) and a lower
recovery rate of demyelinating disease (43%) were observed.57
The differences between these data and the apparent lack
of association between the use of DMD  for biological treat-
ment of RA and the occurrence of demyelinating disease can
be explained by a method bias for registration of cases in each
of these studies, and by the difﬁculty of analysis of an appro-
priate control group.
In contrast, a study with a case–control design, using a
database from a cohort of over 10,000 RA patients, suggested
that anti-TNF agents were associated with an increased risk
of approximately 30% for demyelinating events.58
Regarding the measures employed for the treatment of
neurological manifestations associated with anti-TNF, espe-
cially in cases of CNS manifestations and mononeuritis
multiplex, the following conducts have been described (alone
or in combination): high doses of oral- or pulse therapy
corticosteroids, IV Ig, plasmapheresis, cyclophosphamide,
azathioprine and cyclosporine A. Ig and pulse therapy with
corticosteroids have been the most used methods. The exclu-
sive practice of withdrawal of the biological agent used was
also performed, in some cases with reversion or normalization
of the clinical picture.52
Before starting an anti-TNF, one should evaluate the possi-
bility of previous neurological impairment through the history
and physical examination in order to detect and treat pre-
vious neuropathy conditions. Neurological manifestations in
RA are more  frequent in elderly patients, in the disease with
worse prognostic factors, and in the presence of comorbidities
and other conditions potentially causing, or associated with,
neuropathies. The use of anti-TNF agents is contraindicated
in patients with demyelinating disease – especially in those
with current or prior diagnosis of optic neuritis, demyelinat-
ing peripheral neuropathy and multiple sclerosis. In face of
a suspicion of demyelinating disease, the anti-TNF medica-
tion should be immediately discontinued, seeking to establish
whether there is a causal relationship between medication
use and onset of symptoms. It is suggested that investiga-
tions be carried out and the right documentation be collected,
depending on the type of neurological manifestation, in order
to exclude the possibility of neurological disorders unrelated
to the biological agent.
The treatment should be individualized for each patient,
depending on the severity and neurological manifestations,
and pulse or high-dose corticosteroids, Ig, plasmapheresis,
cyclophosphamide, azathioprine and cyclosporine A can be
used. If re-introduction of a biological agent for control of RA
activity is needed, the preference should be for a non-anti-TNF
agent, such as rituximab (RTX) or abatecept (ABAT).
Gastrointestinal  reactions
Gastrointestinal and hepatic manifestations associated with
anti-TNF are uncommon.Cardiovascular  reactions
Rheumatic diseases of inﬂammatory nature are associated
with high mortality, mostly from cardiovascular mortality.59,60
Several studies have found an increased occurrence of cardio- 0 1 5;5 5(3):281–309
vascular events in RA and AS, and this ﬁnding can be justiﬁed
by the increase in inﬂammatory cytokines such as TNF, an
accelerated atherosclerosis, endothelial dysfunction, use of
other medications that cause cardiovascular morbidity and
mortality, presence of traditional cardiovascular risk factors,
and the genetic heritage of the individual.61
Diseases such as RA, AS and CHF have in common the
presence of high levels of inﬂammatory cytokines, particularly
TNF.62 In this sense, the attempt to treat CHF with anti-TNF
appeared to be an alternative. However, the use of anti-TNF for
the treatment of patients with heart failure (functional classes
III and IV – NYHA) did not show beneﬁt,63 being associated
with a large number of adverse events and deaths, leading to
premature termination of these clinical studies.64 In addition,
some individuals with no previous history of heart disease
developed CHF with this treatment; a complete reversion of
this complication occurred with discontinuation of the anti-
TNF agent.65 This fact led to the termination of studies and put
severe CHF as a contraindication to anti-TNF therapy. Thus,
we had a dilemma: anti-TNF agents could improve, or pos-
sibly trigger or aggravate cardiovascular events in patients
with RA? On one hand, it would be biologically plausible that
the reduction in the inﬂammatory process through the use of
anti-TNF agents would theoretically reduce the risk of heart
failure. On the other hand, the anti-TNF agent could increase
the risk of heart failure in patients with RA, just as occurred
in the general population.66 To try to solve this dilemma, in
this topic we  will analyze studies evaluating anti-TNF and
cardiovascular events in RA, and not in other inﬂammatory
rheumatic diseases, because, in addition of being strongly
associated with cardiovascular events, RA is favored with the
most robust published evidence. A global and individual anal-
ysis of the cardiovascular risk will be performed, taking into
account myocardial infarction (MI), stroke and CHF.
The risk of the use of anti-TNF and cardiovascular events as
a whole was assessed in seven studies involving RA patients,
including a randomized controlled trial, four cohorts, one
case–control study and one cross-sectional study. The gen-
eral conclusion is that anti-TNF therapy reduces the incidence
of cardiovascular events as a whole, with a decline of RR to
0.46 (95% CI: 0.25–0.85).67–71 Seven studies (one cohort, ﬁve
case–control studies and one cross-sectional study) evaluated
the risk of MI in patients with RA and found no differences
between subjects receiving anti-TNF and the control group
(treated with synthetic DMDs), although in those patients who
had a good to moderate EULAR (European League Against
Rheumatism) response after six months of treatment, a RR
reduction of 64% (95% CI: 0.19–0.69%) was noted, compared
with non-EULAR responders.72–78
The risk of stroke with the use of anti-TNF was assessed
in RA patients in four studies (one cohort, one case–control
study and two cross-sectional studies). The conclusion of most
of these studies is that TNF antagonists were not associated
with a risk of stroke, and apparently in those individuals who
responded to anti-TNF and to the continued use of these drugs
for more  than six months, the risk of stroke was reduced.79The occurrence of CHF during the use of anti-TNF in RA
patients was assessed in six studies (ﬁve cohorts and one
case–control study).80–85 The results of these studies were
conﬂicting. Although the use of anti-TNF in elderly patients
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ay be associated with an increased risk of CHF,84 in those
atients aged less than 50 years the conclusion still is not ﬁnal.
The general conclusion on this topic is that the use of
nti-TNF in RA patients appears to be associated with less
ardiovascular morbidity when the changes are evaluated
ogether. However, the individual risk assessment of stroke,
I and CHF still has no deﬁnitive conclusions.
olid  neoplasms
t is speculated if the long-term use of biological DMDs
ould contribute to an increased risk of cancer in patients
ith inﬂammatory diseases. It is not yet clear whether the
alignancy is a consequence of chronic inﬂammation, or
f therapies used to treat inﬂammatory diseases such as
A.86 Studies show that, in RA, there is a greater risk of
ertain malignancies, including lymphoma, lung cancer, non-
elanoma skin cancer and possibly melanoma and leukemia.
urrent evidence suggests that this occurs due to uncontrolled
nﬂammation and possibly to smoking.86
Before the advent of biological DMDs, the incidence of solid
ancers in patients diagnosed with RA mirrored what was
een in the general population, including lung, colorectal, skin,
reast, prostate, bladder, ovary and pancreas neoplasms, and
his scenario has not changed signiﬁcantly since the intro-
uction of new therapies.87 Wolfe and Michaud observed in
3,001 patients from the National Databank for Rheumatic
iseases that the use of biologicals was not associated with
n increased risk of solid tumors.88
Skin tumors are among the possible manifestations
ssociated with the use of anti-TNF agents. Evidence of an
ncreased risk of non-melanoma carcinomata among patients
reated with anti-TNF include one registry data meta-analysis,
rospective observational studies and randomized trials.88–91
he most common neoplasms are non-melanoma skin
ancers, mainly basal cell carcinoma and, less frequently,
quamous cell carcinoma.89–94 Cases of malignant melanoma,
owever, have also been described in patients using anti-TNF
herapy.95–104 Although the exact role of these drugs in the
evelopment of melanomas is not well established, one
hould pay close attention to the appearance of pigmented
esions or changes in the characteristics of preexisting nevi.39
hen in doubt, in order to obtain a correct explanation
f the picture, an histopathologic study of the lesion is
ecommended.
Regarding the recurrence of solid cancer after use of a bio-
ogical agent, little is known due to the exclusion of these
atients in their participation in clinical trials.10 In patients
reated for solid cancer during more  than ﬁve years, we can
ecommend the use of any biological agent. In patients under
ve years of treatment, RTX should be the biological choice.
hus, although no increased risk was observed for cancer,
xcept for non-melanoma skin cancer88–91 in patients using
nti-TNF agents, surveillance for the occurrence of malignan-
ies (including recurrence of solid tumors) in patients treated
ith TNF inhibitors remains appropriate.ymphomas
ince pre-biological times it is known that the estimated risk
f a patient with RA developing lymphoma (especially non-
odgkin’s) is about two times higher than that for general 5;5 5(3):281–309 287
population.105–107 A Swedish case–control study showed that
this risk is directly related to the intensity and duration of the
inﬂammatory process.108,109
TNF is known to have a role in surveillance against the
development of neoplasia; therefore, its inhibition has been
seen as a possible risk factor for the onset of tumors. On
the other hand, coinciding with the beginning of anti-TNF
therapy, the general way to treat this disease changed a lot.
Over the past 15 years, much emphasis was given to early
diagnosis and to a strict control of disease activity. This
change could potentially reduce, for example, the risk for the
onset of lymphoma. Nevertheless, one should not forget that,
until recently, the anti-TNF therapy was restricted to patients
refractory to traditional treatment, i.e., of long duration and
with high inﬂammatory burden. Not surprisingly, therefore,
that the data related to the risk of lymphoma associated with
the use of anti-TNF therapy are conﬂicting.
In a recent meta-analysis involving 63 randomized clinical
trials (RCTs) with 29,423 patients with RA, the risk of lym-
phoma among users of anti-TNF, compared with the risk of
control subjects, was doubled (odds ratio [OR] = 2,1; 95% CI:
0.55–8.4); however, this difference was not statistically signiﬁ-
cant. The authors of this meta-analysis point out that the lim-
ited number of patients and the reduced follow-up time of the
RCTs limit the extrapolation of these data to the prolonged use
of these drugs.110 In the analysis of the ﬁrst cases of lymphoma
among anti-TNF therapy users, half of them were diagnosed
in the ﬁrst eight weeks of treatment.111 To date, there is no
evidence of the emergence of an increasing risk of lymphoma
related to the prolonged use of anti-TNF agents.86,112
One SLR and a meta-analysis of observational studies
and registries, also recently published, conﬁrmed that, com-
pared with the general population, patients treated with TNF
inhibitors have an increased risk of lymphoma (standardized
incidence ratio = 2.55, 95% CI: 1.93–3.17).89,113–115 But when
compared with RA patients treated with synthetic drugs, this
increase in the risk for lymphoma was not observed (estimated
risk = 1.11, 95% CI: 0.70–1.51).88,116,117
Immunogenicity
Anti-human chimeric antibodies (HACA) and human anti-
human antibodies (HAHA) may occur with the use of any of the
drugs in this class, but their effect on the effectiveness of ther-
apy is unclear. The induction of antibodies against anti-TNF
agents depends mainly on their structure. Chimeric molecules
have a greater capacity to induce immunogenicity, compared
with fully human drugs. Among anti-TNF agents, this phe-
nomenon has been studied mainly in IFX users, especially
in those with RA or Crohn’s disease. The prevalence of anti-
IFX antibodies in RA ranges from 12% to 44% and appears to
be inversely related to serum levels and to the therapeutic
response to medication. The use of ETN was associated with
the development of anti-ETN antibodies in 0–18% of patients,
without any apparent impact on the efﬁcacy or on the occur-
rence of adverse events. Studies in patients with RA and with
Crohn’s disease show the presence of anti-ADA antibodies
in 1–87% of patients. In 25 children with juvenile idiopathic
arthritis, 8% had anti-ETN antibodies.118,119
The methods more  often used for the detection of HACA
and HAHA are ELISA (Enzyme Linked Immuno Sorbent Assay)
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and radioimmunoassay. The presence of anti-IFX antibodies
in RA patients may suggest a poorer therapeutic response and
an increased risk of infusion reaction. However, perhaps these
same conclusions may not be observed in relation to anti-ADA
and anti-ETN antibodies. Immunological tolerance to ADA and
IFX may be increased with a concomitant use of immunomod-
ulators such as MTX  and azathioprine. There is no evidence
in the literature of cross-reactivity of HACA and HAHA for the
different anti-TNF agents.119
Other  reactions
Among the manifestations not previously mentioned, those
of dermatological origin are of special interest. Skin condi-
tions described in anti-TNF inhibitor users may didactically
be divided into: skin reactions related to their administration,
skin infections, skin neoplasms (previously mentioned) and
immune-mediated diseases.
Among the immune-mediated diseases, the onset of pso-
riasis has been described following the use of several drugs
such as anti-malarials, anti-inﬂammatory drugs and beta-
blockers.97 In the case of association of psoriasis with the
use of anti-TNF, the aspect that seems paradoxical is the
onset of psoriatic skin lesions with the use of a drug indi-
cated for their treatment. The prevalence of this phenomenon
is varied, but according to some studies, it lies between
0.6% and 5.3%.98,99,120 The mean latency time between the
start of the TNF inhibitor and the onset of skin lesions is
10 months; however, this time may vary from several days
to several years.97,101–103 The three main types of psoriatic
lesions observed are: pustular, about 56%; en plaque,  in half
of the cases; and guttate in about 12% of the cases.104 In
approximately 15% of the patients, more  than one type of
lesion is present.104 The most characteristic clinical form
associated with the use of TNF inhibitors is pustulosis
palmoplantaris.104
Initially, these lesions were considered as a hypersensi-
tivity reaction to the drug. Subsequent histological studies,
however, showed that the lesions were identical to those
occurring in people with idiopathic psoriasis.102,120 In general,
patients who develop this type of adverse effect had displayed
a good response to anti-TNF, such that the appearance of the
skin lesion affects negatively the effectiveness of the treat-
ment.
Considering that most of the described cases of this
association occurred in RA patients, we cannot forget that,
from the beginning, it may be a case of PA, since in up
to 15% of the patients with this illness the joint condi-
tion emerges before the skin condition. On the other hand,
maybe this could be only the case of an association of
two conditions that are not rare.104 The coexistence of pso-
riasis and RA, however, is infrequent (about 2%), while
the onset of psoriasis induced by TNF inhibitors occurs in
about 3% of the patients with spondyloarthritides and in
2–5% of those with RA, an incidence much higher than
expected.98,102,120
Reports of cutaneous lupus,121–124 alopecia areata,99,125–133
134–138 135,139,140cutaneous vasculitis, vitiligo, relapsing
polychondritis,141 polymyositis/dermatomyositis,142,143 local-
ized scleroderma (morphea),144–146 granuloma annulare,135,147
lichen or lichenoid reaction,120,135,148 and pemphigus149–151 0 1 5;5 5(3):281–309
were described with the use of TNF inhibitors. The cause and
effect relationship of these associations, however, are not
well established.
Vaccination  response
Regarding vaccination, the response to inﬂuenza vaccine does
not seem to be impaired in patients using anti-TNF agents,
even when combined with MTX.152–154 However, an author
showed a reduced response to this vaccine, when evaluating
patients using IFX associated with MTX  or ETN.155 Similarly,
a study conducted in Brazil, evaluating the H1N1 inﬂuenza
vaccine, found, besides a good safety proﬁle, a reduced serum
protection in RA patients, regardless of disease activity. MTX
was the only DMD associated with reduced response to the
vaccine.156 As for the pneumococcal vaccine, the use of MTX  in
isolation, or its use combined with some anti-TNFs (ADA, ETN
and IFX), may decrease the effectiveness of the vaccine, while
the use of these biologicals in isolation does not inﬂuence the
vaccine response.153,155 Additionally, the use of anti-TNF could
signiﬁcantly reduce the response to hepatitis B vaccine.157
Vaccines with live attenuated components should prefer-
ably be administered three to four weeks before initiation of
immunosuppressive therapy, to ensure that viral replication
ﬁnished before the alteration of the immune competence of
the patient (in terms of drug use). Otherwise, under treatment,
the vaccination should be delayed for at least the equivalent
time of four half-lives of each anti-TNF drug.158
T-cell  co-stimulation  blocker  –  ABAT
ABAT is a human fusion protein consisting of the extracellular
domain of human CTLA-4 linked to the modiﬁed Fc portion
of human immunoglobulin (Ig) G1. This drug inhibits T-cell
activation for binding to CD80 and CD86, thereby blocking its
interaction with CD28 (the co-stimulation receptor).159 ABAT
was approved in December 2005 by the Food and Drug Admin-
istration (FDA) for RA patients, both for therapeutic failure
with synthetic, as biological, DMDs. In Brazil, the SBR Consen-
sus (2012) on treatment of RA suggest that ABAT can be used
in patients with active RA that failed with synthetic DMDs,
preferably when these drugs were used in combination, or
after the use of an anti-TNF. ABAT can be used preferably as
monotherapy, or combined with a synthetic DMD.37
A SLR on the use ABAT in RA patients pooled seven stud-
ies and 2908 patients. In this SLR, total adverse events were
slightly more  common with ABAT compared with placebo
(RR = 1.05, 95% CI: 1.01–1.08) and severe infections in 12
months were more  common with ABAT versus control group
(OR = 1.91, 95% CI: 1.07–3.42).160 Pooled data from 4149 patients
enrolled in several pivotal studies demonstrated that the inci-
dence of serious adverse events (95% CI) with ABAT is very low,
with gradual decrease at each year.161,162
Regarding security of ABAT interaction with MTX  or other
DMDs, the extension of the AIM (Abatacept in Inadequate
responders to Methotrexate) study showed efﬁcacy and safety
163of ABAT combined with MTX. The ASSURE (Abatacept Study
of Safety in Use with Other RA Therapies) study also showed
safety of combining ABAT with MTX and with hydroxychloro-
quine, sulfasalazine, leﬂunomide or azathioprine.164
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nfections
BAT is contraindicated in patients with active infections,
ncluding skin ulcers, infected prostheses, and in catheter
sers.165 The risk of serious infection is reported in 2.9% with
BAT versus 1.9% for placebo.164 The combination with other
iologicals increases the risk (serious infection 5.8% versus
.6%).164 ABAT does not increase Mycobacterium tuberculosis
nfection, and only nine cases of tuberculosis in 4149 patients
reated over time (12, 132 patient-years) have been reported.162
 study with mice demonstrated the safety of this drug in
elation to tuberculosis infection.166 In this study, chronic M.
uberculosis infection was caused in C57BL/6 mice. After four
onths of induced infection, mice were treated with different
iological agents for up to 16 weeks in three different groups
one group with ABAT and the other two with anti-TNF or
lacebo). In mice treated with placebo and ABAT, tuberculosis
ontrol was maintained, with 100% of survival after 16 weeks
f treatment. Mice treated with anti-TNF had 100% of mortal-
ty at nine weeks, with weight loss and increased bacterial load
n the lungs, lymph nodes and spleen. Thus, it was concluded
hat ABAT did not exacerbate the infection with M. tuberculosis
n mice.166
As for those patients who initiated their treatment with
ther biological agents, screening tests for hepatitis B and C
ust be performed before the start of ABAT.161
nfusion  reactions
he infusion reactions with ABAT are rare, with 3.9/100
atient-years in six studies reviewed involving 3755
atients.162 The most common symptoms are dizziness,
ausea, headache and hypertension. Severe hypersensitivity
eactions are rare (0.4% versus 0.2% with placebo).162,167
ematological  reactions
o date, no studies evaluating hematological changes and
BAT in rheumatic diseases were published.
eurological  reactions
o date, no reports of peripheral neuropathy or CNS involve-
ent associated with the use of ABAT were published.
astrointestinal  reactions
iver enzyme changes are mild and rare in patients treated
ith ABAT (0.1–1% of patients) and thus have little clinical
alue. It appears that the combination with MTX, NSAIDs, cor-
icosteroids, sulfasalazine and leﬂunomide does not increase
he occurrence of hepatotoxicity.161
ardiovascular  reactions
egarding the increased cardiovascular risk in patients
ith RA, studies have shown that the use of ABAT deter-
ines no greater risk.161,162 Cardiovascular disease does not
ontraindicate the use of ABAT and this drug does not inter-
ct with cardiovascular drugs, nor with the use of oral
nticoagulants.162
eoplasmsolid  neoplasms  and  lymphomas
he risk of malignancies, e.g., non-melanoma skin cancer,
ung cancer, colorectal cancer and breast cancer, for ABAT 5;5 5(3):281–309 289
users is comparable with the risk for RA patients in use of syn-
thetic DMDs.162 One study analyzed seven clinical trials with
4134 patients versus RA patients from ﬁve cohorts (41,529 RA
patients, with a mean follow-up between 1.8 and 9.3 years). In
the population treated with ABAT, a lymphoma rate similar to
that in different cohorts of RA was found, with a standardized
incidence rate = 0.89 (95% CI: 0.36–2.15).168
Regarding the risk of lymphoma and other hematologi-
cal diseases, double-blind and open studies involving 4149
patients treated with ABAT (11,658 patient-years) showed
hematologic malignancy occurring only in 0.13/100 patient-
years (similar to RA), but just as with anti-TNF biologicals, the
use of ABAT should be avoided in patients who  had lymphoma
over the past ﬁve years.161
Immunogenicity
Unlike what was observed with the use of anti-TNF biologi-
cal DMDs, antinuclear antibodies (ANA) and anti-DNA did not
become positive over time in patients treated with ABAT.162
There appears that the formation of HACA and HAHA using
ABAT does not occur.
Other  events
The use of ABAT is contraindicated in patients with signs
of chronic obstructive pulmonary disease (COPD), because of
the exacerbation of dyspnea and an increased occurrence
of infections.37 Studies were published on the occurrence of
psoriasiform rash,169 as well as lupus-like syndrome and Sjö-
gren syndrome,170 possibly in association with the use of
ABAT.
The risk of development of autoimmune events with the
use of ABAT, based on pooled data of 4149 patients and
12,132 patient-years, showed rare cases of cutaneous psori-
asis (OR = 0.60), Sjögren’s syndrome (OR = 0.26) and vasculitis
(OR = 0.34).162
Vaccination  response
Regarding vaccination in RA patients in use of ABAT, a sub-
analysis of the ARRIVE (Abatacept Researched in RA Patients
with an Inadequate anti-TNF response to Validate Effective-
ness) study evaluated the efﬁcacy and safety of inﬂuenza
vaccination in 20 patients.171 A total of 55%, 50% and 35% of
the patients developed vaccine response to H1N1, H3N2 and
inﬂuenza B virus strains, respectively. A study in Brazil inves-
tigated the humoral response to vaccination against H1N1
ﬂu virus in 11 RA patients treated with MTX  in combination
with ABAT.172 Only 9% of the patients treated with the combi-
nation of MTX and ABAT achieved seroprotection, compared
with 58% of patients treated only with MTX and with 70%
of healthy individuals. Schiff et al. investigated the response
to anti-pneumococcal vaccine in 21 patients with RA treated
with ABAT in a sub-analysis of the ARRIVE study.173 Of these
21 patients, 81% exhibited immune response to at least one
serotype.173
B-cell  depletion  drug  –  RTXRTX is a monoclonal antibody directed against lympho-
cytes CD20+ in patients with RA in moderate to severe
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activity, with treatment failure to an anti-TNF agent.37,174
RTX is used preferably in combination with MTX, and
may be prescribed in association with other DMDs. RTX
has a better therapeutic response in patients with positive
serology for rheumatoid factor (RF) and/or anti-cyclic cit-
rullinated peptide (anti-CCP) antibodies.175 Individuals with
good response to treatment may be subjected to a new
course of RTX if the disease is reactivated in a time interval
<6 months.176
In a meta-analysis that included 938 patients treated with
RTX and unresponsive or intolerant to synthetic DMDs or anti-
TNF agents followed during 24–48 weeks, it was observed that
the incidence of adverse effects in all systems was not higher
than in those patients treated with placebo (RR: 1.062, 95% CI:
0.912–1.236, p = 0.438). With regard to the number of patients
who  experienced at least one serious adverse event, no signif-
icant difference between those treated with RTX and placebo
was observed (RR: 0.855, 95% CI: 0.622–1.174, p = 0.333).177 The
long-term safety after multiple infusions of RTX was also ana-
lyzed in a recent publication.178 Submitted data are pooled
from eight RCTs and two open-label extension studies, includ-
ing a total of 3194 patients who  received up to 17 courses
of RTX over 9.5 years (4418 patient-years). The percentage of
infections and serious adverse events remained stable over
time and after multiple infusions.178
RTX is contraindicated in patients with hypersensitivity to
this drug or to other murine proteins, with active infection and
severe heart failure.179
Infections
With regard to infections, a meta-analysis that included 745
patients treated with RTX in three RCTs found that there
was no increased risk for serious infections compared with
placebo.180
In the aforementioned study by van Vollenhoven et al.178
the percentage of serious infections was 3.94/100 patient-
years (3.26/100 patient-years in patients observed for more
than ﬁve years) and was comparable to that for the
placebo group associated with MTX  (3.79/100 patient-years).
A decrease in Ig levels was observed from four months, after
at least one course of RTX, but the clinical signiﬁcance of
this is uncertain. The subgroup of patients with low IgG lev-
els showed a higher risk of serious infections compared to
patients who never presented this ﬁnding, but the risk of infec-
tion was already increased in these patients, even before the
onset of IgG level decrease. IgG levels must be measured prior
to treatment with RTX and monitored over time.179 Low levels
of IgM were not associated with an increased risk of infection.
Regarding tuberculosis, RTX is approved for patients who
do not respond or are intolerant to anti-TNF. Thus, most
patients who used RTX have been pre-selected for latent tuber-
culosis in clinical trials and in daily practice. With that in
mind, reactivation of tuberculosis was not observed, despite
the package insert recommending a search for latent tubercu-
36,181losis before starting the medication.
Regarding hepatitis B and C, experts recommend that sero-
logy for hepatitis B should be performed prior to initiation of
treatment with RTX.179 Reactivation has been documented in 0 1 5;5 5(3):281–309
both negative and positive patients to hepatitis B virus surface
antigen (HBsAg),182,183 emphasizing the need to investigate
not only HBsAg, but also other antibodies against core anti-
gen (HbcAg – hepatitis B core antigen) to identify a positive
state of carrier. The negativity for HBsAg (also with negativ-
ity for anti-HBs antibodies) identiﬁes the group of patients
requiring vaccination prior to immunosuppressive therapy.
A search for hepatitis B virus DNA (HBV-DNA) is not indi-
cated as screening tool, but for investigation of viral load
and response in chronic infection established by hepatitis
B. Although there is variation among currently existing rec-
ommendations, it is generally considered that those HbsAg-
and/or anti-HBc-positive patients should be treated prophy-
lactically. The treatment of occult infection by hepatitis B
virus with anti-HBc-positive in isolation remains uncertain:
in such patients, HBV DNA could be determined, and then
prophylaxis could be considered, with close patient mon-
itoring. Routine evaluation for hepatitis C should also be
considered.184–189
Infusion  reactions
The most frequent adverse events are infusion reactions,
which occur in 30–40% of the patients during the ﬁrst infu-
sion and about in 10% at second infusion.190 In most cases,
the reactions are of mild to moderate intensity. Severe cases
requiring drug discontinuation occur in less than 1% of treated
patients.179 Sixty minutes before each RTX infusion, the
patient must be treated with IV methylprednisolone 100 mg,
acetaminophen 1 g and antihistamines, to reduce severity and
frequency of infusion reactions.190
Hematological  reactions
The effect on B lymphocytes with depletion of these cells is
expected, and is part of the action mechanism of this drug.
However, a signiﬁcant reduction in total lymphocyte count
is not expected. The safety of B-cell depletion after multiple
infusions of RTX, especially related to the cumulative risk of
serious infections and malignancies, is not fully established
in patients with RA.178 Hematologic adverse events have not
been shown to be relevant in long-term studies.178,191
Neurological  reactions
To date, six cases of MLE were reported in patients with RA
treated with RTX.178,179 Most cases had long-term RA and
were users of multiple immunosuppressants. The number
of reported cases of MLE in patients diagnosed with RA in
use of RTX confers a risk of 0.4/100,000 patient-years, slightly
increased compared to the general population (0.2/100,000)
and lower than that observed in patients with systemic lupus
erythematosus (4/100,000).53 Thus, although the occurrence is
considered rare (1:20,000) due to the high morbidity and mor-
tality of the condition, clinical surveillance for this diagnosis
is recommended in this patient population.
To date, no reports of peripheral neuropathy associated
with the use of RTX were published.Gastrointestinal  reactions
Increases in gastrointestinal adverse events after exposure to
RTX have not been observed.178,192
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ardiovascular  reactions
ncreased risk of acute MI  over time in patients treated with
TX has not been observed.178
eoplasms
olid  neoplasms  and  lymphomas
ncreased risk of solid or hematological malignancies over
ime in patients treated with RTX with an observational period
f approximately 10 years has not been observed.178
mmunogenicity
afety data from long-term RCTs on RA patients indicate
hat 11% (273/2578) of the patients exposed to RTX develop
ACA.191 HACA-positive patients did not show a higher num-
er of infusion reactions during the second course of RTX,
ompared with HACA-negative patients.
ther  events
ew cases of psoriasiform conditions have been reported after
TX infusion for the treatment of rheumatic diseases or other
ndications. A series of three cases was described in two
atients with RA and in one with SLE, requiring speciﬁc treat-
ent for psoriasis and RTX discontinuation.192
Pulmonary manifestations were identiﬁed in a system-
tic review study with 121 cases of interstitial lung disease.
nly nine of these patients had indication of RTX for treat-
ent of rheumatic diseases, including three cases of RA,
ne of them in association with Castleman’s disease. In this
eview, the interstitial lung disease was considered as a rare
vent, but with potential for morbidity and mortality. All cases
ad imaging (radiographs and/or computed tomography) ﬁnd-
ngs. Pulmonary function tests, when performed, showed
 deﬁcit of diffusion capacity and a restrictive respiratory
attern.193
In a series of 43 patients with autoimmune diseases,
n two cases of patients with systemic lupus erythemato-
us, and in one case of primary Sjögren’s syndrome, mild
ever type reactions, arthralgia, rash, and urticaria-like lesions
ere observed; and in one case the medication had to be
iscontinued.194 We did not ﬁnd similar reports in patients
ith RA or spondyloarthritides. There are case reports of
erum sickness, with the appearance of mild to moderate dis-
ase after infusion of RTX.195
accination  response
he use of RTX is associated with a reduced response to
oth T-cell independent and T-cell dependent vaccines.158
here is evidence to suggest a compromised response to
nti-pneumococcal and inﬂuenza vaccines, when adminis-
ered to patients receiving RTX.179,196,197 The response to
nﬂuenza vaccine (also including A and H1N1 vaccines) is also
articularly compromised when the vaccine is administered
arly, four to eight weeks after administration of RTX. Thus,
nﬂuenza and pneumococcal vaccines must be applied before
tarting RTX, or six months after the 1st infusion and four
eeks before the next dose.158,179 High-risk patients for con-
racting tetanus and treated with RTX within the last 24 weeks
hould use passive immunization with tetanus Ig. Hepatitis B 5;5 5(3):281–309 291
is another vaccine that should be administered before the use
of RTX.179
Interleukin-6  (IL-6)  receptor  blocker  –
tocilizumab  (TOCI)
TOCI is a humanized monoclonal antibody directed against
the receptor of IL-6, including soluble and plasma membrane-
bound fractions, and able to blocking their cellular actions.
TOCI is not only used in the treatment of RA activity in
combination with MTX  or other DMD, but also as monother-
apy and in patients with an inadequate response to MTX
or other DMDs, or to TNF blockers.37 In general, monitor-
ing should be continuous for all adverse events related to
TOCI. However, some of them are more  related to the initia-
tion of treatment and tend to present a subsequent reduction
in the frequency of occurrence, such as infusion reac-
tions and changes in lipid and liver transaminases’ plasma
concentrations.
The data on TOCI safety proﬁle were pooled from 24-
week randomized, placebo-controlled clinical trials (RPCCTs)
considered pivotal for registration and approval of this
drug, but also from longer-term studies, including results of
registry trials and post-marketing surveillance studies, par-
ticularly of FDA and EMEA (European Medicines Evaluation
Agency).
Infections
Like other immunobiological agents, TOCI should not be used
in patients with active infection by any pathogen, includ-
ing bacteria, viruses, fungi and parasites.198,199 Traditionally,
C-reactive protein (CRP) is used as a biomarker for tracking
infections. However, CRP is not useful for TOCI users, since a
signiﬁcant reduction in plasma concentration of CRP occurs
after using that agent. So far, there is no evidence demon-
strating the ability of TOCI in suppressing febrile response.
Recent Cochrane meta-analysis, including 8 RPCCTs, showed
an infection risk 1.2 times greater for patients treated with
TOCI versus those using synthetic DMDs,36,200 in accordance
with data previously published by the Nishimoto group.201
However, this risk does not increase with time of exposure,
showing a major event rate ranging from four to six per
100,000 patient-years,202 even if combined with other syn-
thetic DMDs.203
Unlike TNF blockers, TOCI did not increase the risk of TbL
reactivation.204 However, a screening for LTBI is still recom-
mended before and during use of immunobiological agents,
especially in endemic areas. In Japan, there was no increase
in the number of cases of disease caused by non-tuberculous
mycobacteria.205
Recent evidence revealed no increase in the rate of surgical
wound infection in patients with RA in use of TOCI after under-
going total knee or hip arthroplasty.206 The suspension of TOCI
at least for four weeks before the procedure is recommended.
After pooling retrospectively information on infectious condi-
tions occurring after orthopedic surgery (arthroplasty) in the
period 1999–2010, Momohara et al. observed more  delay for
surgical wound healing (20/122, 16.4%) than infections (3/122,
 o l . 2292  r e v b r a s r e u m a t
2.45%) in the TOCI group, especially when the surgical proce-
dure involved the foot and the column.207
Regarding B and C viral hepatitis, the data obtained
from studies are still preliminary, since these patients were
excluded from RPCCTs. At the moment, TOCI should not be
used in this clinical setting.204,208
As for opportunistic infections, the rate is low, ranging from
0.2 to 0.3 for every 100,000 patient-years. Fungal infections are
the most reported.203
Infusion  reactions
These are rare events with TOCI and can be minimized by
slowing the rate of IV infusion and/or by administration of
premedication with corticosteroids. Severe anaphylactic reac-
tions and the need for permanent discontinuation of TOCI are
quite rare.
Hematological  reactions
Studies with small numbers of participants have shown that
one of the major hematologic adverse events related to TOCI
is neutropenia.209 The mechanism responsible is still not well
known, but it appears to be related to a direct immunological
role or to IL-6 receptor blockage in these cells.
In general, the neutropenia is transient and of low inten-
sity, and does not increase the risk of infection per se. More
severe or prolonged cases require reducing the dose of medi-
cation to 4 mg/kg infusion; if the problem is not resolved, the
medication should be permanently discontinued.210
Neurological  reactions
There is only one case report of peripheral neuropathy related
to the use of TOCI.210
Gastrointestinal  reactions
Elevations of liver enzymes may occur in 8–10% of the patients,
regardless of synthetic DMDs, as with other cytokine block-
ers. These elevations are usually mild and transient, and do
not increase the risk of irreversible hepatocellular injury.211
When the treatment is initiated, monitoring the patient every
four to eight weeks is recommended, and then every three to
six months. Persistent elevations suggest the need for a more
comprehensive investigation into other causes, besides a dose
reduction and discontinuation of medication.203
Some cases of intestinal (especially colonic) perforation
have been reported in patients using TOCI. One hypothesis to
explain this ﬁnding is the possibility of subclinical diverticuli-
tis. Thus, an anamnesis directed for previous history of colonic
diverticular disease and diverticulitis is recommended. This
risk increases with concomitant use of corticosteroids and
NSAIDs; therefore, these medications should be used spar-
ingly in this scenario.203
Cardiovascular  reactions
No consistent clinical studies were published evaluating car-
diovascular events as primary outcomes, with use of TOCI in
patients with rheumatic diseases. However, Schiff et al., when
assessing over eight thousand patients from RPCCTs with RA
using TOCI, observed low incidence of AMI (0.25/100 patient-
years) and stroke (0.19/100 patient-year) and no increase with
a longer exposure to the drug (2006–2010).203 0 1 5;5 5(3):281–309
Neoplasms
Solid  neoplasms  and  lymphomas
After reviewing data from 63 RPCCTs with more  than 29,000
patients with RA, no increased risk of solid or hematological
malignancies was observed in the ﬁrst 24 weeks, when com-
pared with a control group treated with synthetic DMDs.110
In the longer term, register data have not been published
so often, when compared with TNF blockers’ data. However, in
the light of current knowledge, it seems that there is no higher
risk of neoplasia among patients using TOCI, compared with
what was observed in the control group.212
Immunogenicity
Taking into consideration that this is an immunobiological
agent, TOCI have antigenic potential, although immunogenic
reports published are scarce. The ability of formation of HAHA
neutralizing antibodies, including intensity, isotype, speci-
ﬁcity and kinetics, has been studied, but the frequency is much
lower than that reported for TNF blockers.213
Other  events
There are some anecdotal cases or case reports of patients
who developed other unexpected adverse reactions after
TCZ, including skin (ulcers, necrotizing fasciitis)214 and
mucosal (persistent aphthous ulcerations in the oral mucosa)
conditions,215 as well as ocular (bilateral retinopathy with
hemorrhage and cotton-wool inﬁltrates),216 and lung (orga-
nizing pneumonia and exacerbation of interstitial conditions)
events.217,218
Just as observed with TNF antagonists, some initial cases
(de novo) of psoriasis and uveitis have been reported after IL-6
blockade, emphasizing paradoxical events that may occur also
with the use of this medication.219–221
Vaccination  response
To date, only few studies on vaccine response in patients
treated with TOCI were published. Two studies demonstrated
an adequate safety and efﬁcacy proﬁle (seroprotection and
seroconversion) for inﬂuenza vaccine in patients with RA,
regardless of MTX222 and systemic onset juvenile idiopathic
arthritis.223 In addition, no exacerbation of the joint scenario
in these patients was observed. Regarding other vaccines and
immunizations, there are no data on the safety and efﬁcacy
proﬁle.
Table 1 presents the main adverse events resulting from
treatment with biological DMDs for RA and spondyloarthri-
tides.
Biologicals,  pregnancy  and  lactation
Some rheumatic diseases for which biological DMDs  are
indicated, such as RA, affect disproportionately females,224
including patients of childbearing age, when pregnancy can
occur in a planned or unplanned way.
The use of medications during the conception, pregnancy
and lactation periods causes great anxiety for the pregnant
patient and also for her physician, who must prescribe these
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Table 1 – Main adverse events resulting from the use of disease-modifying drugs (DMD) for the treatment of rheumatic diseases.
Drugs  (mechanism
of action)
Infections  Infusion  reactions Hematological
reactions
Neurological
reactions
Gastrointestinal
reactions
Cardiovascular
reactions
Solid  neoplasms  Hematological
neoplasms
Immunogenicity  Other  occurrences  Vaccine  response
Anti-TNF
(adalimumab  –
ADA,
certolizumab  –
CERT,  etanercept
– ETN,
golimumab  –
GOL,  inﬂiximab  –
IFX)a
Infections,
bacterial  or  viral,
are  the  most
frequent  and
important  adverse
events  arising  from
the  use  of anti-TNF,
mainly  affecting
the respiratory
tract,  skin,  soft
tissues  and  urinary
tract.27 The  risk  of
hospitalization
caused  by  bacterial
infection  is two
times  higher  in  the
patient  using
anti-TNF  than  in
patients  on  MTX
alone;  this  risk
increases four
times when
considering  the
ﬁrst  six  months  of
treatment.28 Since
TNF  plays  a central
role  in  the
formation  and
maintenance  of  the
granuloma,
tuberculosis  is an
adverse  event  that
potentially  should
be  very  frequent,  if
it had  not  been  for
its  systematic
prevention,  which
should  never  be
neglected.34–36 In
the presence  of
infection  by
hepatitis  B  and  C
viruses,  the  use  of
anti-TNF  should  be
avoided.  In
exceptional  cases
of  infection  by
hepatitis  C virus,
anti-TNF  drugs  can
be used  with  the
associated  antiviral
treatment.37
Most  skin  reactions
related  to the
administration  of
TNF  inhibitors
have mild  to
moderate  intensity,
and  do not  require
discontinuation  of
the drug.39 The
most common
reactions  are:
erythema, urticaria
and  eczema  or
rash,  which  may,  in
turn,  be
accompanied  by
pain  or edema.39
While  the
appearance  of  rash
has  been  described
in approximately
6.9% of  the  patients
receiving  IFX,40
injection  site
reactions were
reported in  40%  of
the cases  with
ETN41 and  15%
with ADA.42 With
the new  anti-TNF
antibodies,  the
incidence  of
injection  site
reactions appears
to be  smaller:  2.3%
with  CERT43 and
2.4% with  GOL.44
The  use  of  anti-TNF
agents  seems  to  be
associated  with  low
risk of  hematological
changes,
thrombocytopenia
being a  very  rare event,
and  leucopenia  caused
by a  severe
neutropenia  being  the
most frequent
manifestation.37,45–49
As  a routine,  the  cell
blood  count  could  be
useful  immediately
before start  of
immunobiological
agents  and  through  the
follow-up  of  these
patients.
Neurological
manifestations
have  been
described  in
patients  using
anti-TNF therapy,
including  with
exacerbation  or
onset  of multiple
sclerosis,
Guillain–Barré
syndrome,
multifocal
leukoencephalopa-
thy (MLE),  optic
neuritis and
various forms  of
demyelinating
peripheral
neuropathy.  The
prevalence  of
demyelinating
disease  induced  by
the  use  of  anti-TNF
is  estimated
between  0.02%  and
0.20%.  The  use  of
anti-TNF  therapy  is
contraindicated  in
patients  with  a
demyelinating
disease  such  as
optic  neuritis,
peripheral
demyelinating
neuropathy  and
multiple  sclerosis.
On suspicion  of a
demyelinating
disease,
discontinue
anti-TNF
immediately  and
seek  to  establish
the  causal  link
between  the  use
and  the  symptoms.
Undertake  a
research  and
proper
documentation,
depending  on  the
type  of
neurological
manifestation.
Treatment  should
be  individualized
for each  patient,
depending on  the
severity  of the
clinical
picture.50–58
Gastrointestinal
and  hepatic
manifestations
associated  with
the  use  of
anti-TNF  are
unusual.
The use  of
anti-TNF  in  RA
appears  to  be
associated with
lower
cardiovascular
morbidity  when
the  manifestations
are jointly
evaluated;
however,  the
individual
assessment  of  the
risk  of stroke,
myocardial
infarction  (MI)  and
congestive  heart
failure  (CHF)  still
has  no  deﬁnitive
conclusions.  CHF
class  II  or  IV (New
York Heart
Association  –
NYHA)  is a
contraindication
for  prescribing
anti-TNF
drugs.59–85
While  no  increased
risk for  neoplasia
was observed
(except  for
non-melanoma
skin cancer)  in
patients  using
anti-TNF  agents,
surveillance  for the
occurrence  of
malignancies
(including
recurrence  of solid
tumors)  in patients
treated  with  TNF
inhibitors  remains
appropriate.86–104
Compared
with  the
general
population,
patients
treated with
TNF inhibitors
have an
increased  risk
of lymphoma.
However,
when
compared
with  patients
with RA
treated with
conventional
drugs, no
increased  risk
for lymphoma
and  other
hematologic
malignancies
was
observed.105–117
HACA  (human
anti-chimeric
antibodies)  and
HAHA  (human
anti-human
antibodies)  can
occur  with  all
drugs of  this  class,
but  their  effect  on
the  effectiveness  of
therapy  is unclear.
The  induction  of
production  of
antibodies  against
anti-TNF  agents
depends mainly  on
its structure.
Chimeric  drugs
have  a  greater
capacity  to  induce
immunogenicity
compared  to  fully
human
drugs.118,119 The
immunological
tolerance to ADA
and  IFX may  be
increased  with
concomitant  use of
immunomodula-
tors, such  as
methotrexate  and
azathioprine.
There  is no
evidence in  the
literature  that
HACA and  HAHA
cross-react  with
the  different
anti-TNF
agents.125
Dermatological
manifestations  described  in
users  of  anti-TNF  inhibitors
include  skin  reactions
related  to  its
administration,  skin
infections,  skin  cancer  and
immune-mediated
diseases, such  as
psoriasis97–99,101–104
cutaneous  lupus,121–124
alopecia  areata,99,125–133
cutaneous
vasculitis,134–138
vitiligo,135,139,140
relapsing
polychondritis,141
polymyositis/
dermatomyositis,142,143
localized  scleroderma
(morphea),144–146
granuloma  annulare135,147
lichen  or lichenoid
reaction120,135,148 and
pemphigus.149
The  response  to
inﬂuenza  vaccine  does
not appear  to  be
impaired  in  patients
using  anti-TNF  agents,
even  when  combined
with MTX.152–154 A
study conducted  in
Brazil and  that
evaluated the  vaccine
against  H1N1  inﬂuenza,
found,  besides  a good
safety  proﬁle,  reduced
serum  protection  in
patients  with  RA
independently  of
disease  activity.  MTX
was  the  only  DMD
associated  with  reduced
response  to  the
vaccine.156 As for the
pneumococcal  vaccine,
the use of  MTX  in
isolation  or  combined
with  some  anti-TNFs
(ADA, ETN  and  IFX),
may  decrease  the
effectiveness  of  the
vaccine,  while  the
isolated  use  of  these
biologicals  does  not
inﬂuence  the  vaccine
response.153,155
Additionally,  the  use  of
anti-TNF  can
signiﬁcantly  reduces  the
vaccine  response
against hepatitis  B.157
Vaccines  with  live
attenuated  components
should preferably  be
given  three  to  four
weeks  before  initiation
of  immunosuppressive
therapy,  to  ensure  that
viral  replication  has
ﬁnished  before  the
change  of  the  patient’s
immune  competence  (in
terms  of  drug  use).
Otherwise,  under
treatment, the
vaccination  should  be
delayed for  at  least  the
equivalent  time  of  four
half-lives of  each
anti-TNF drug.158
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Table 1 (Continued)
Drugs  (mechanism
of action)
Infections  Infusion  reactions Hematological
reactions
Neurological
reactions
Gastrointestinal
reactions
Cardiovascular
reactions
Solid  neoplasms  Hematological
neoplasms
Immunogenicity  Other  occurrences  Vaccine  response
data  from  studies
are still
preliminary.  At  the
moment,  TOCI
should not  be used
in  this  clinical
setting.204,208
personal  history  of
colonic  diverticular
disease  and
diverticulitis  is
recommended.
This  risk  increases
with  concomitant
use of
corticosteroids  and
NSAIDs.  Therefore,
in this  scenario
these drugs  should
be  used
sparingly.203
ABAT, abatecept; ADA, adalimumab; anti-TNF, tumor necrosis factor blocking drugs; RA, rheumatoid arthritis; apoB/apoA, apolipoprotein B/apolipoprotein A; Str., stroke; CERT, certolizumab; DMD,
disease-modifying drug; RPCCT, randomized placebo-controlled clinical trial; ETN, etanercept; GOL, golimumab; HAHAs, human anti-human antibodies; HDL, high-density lipoproteins; IFX, inﬂiximab;
MI, myocardial infarction; CHF, congestive heart failure; LTBI, latent tuberculosis infection; LDL, low density lipoproteins; MTX, methotrexate; TOCI, tocilizumab.
a Most available data on the occurrence of adverse effects concern to the ﬁrst anti-TNF agents: inﬂiximab, etanercept and adalimumab. There are no deﬁnitive comparative studies. Meta-analyses
and the assessment of observational studies showed no signiﬁcant difference in the incidence of complications among different biological agents. Albeit with shorter observation time, the current
understanding is that the newer anti-TNF agents, e.g., golimumab and certolizumab pegol, are associated with the same risk of adverse events.
 o l . 2298  r e v b r a s r e u m a t
drugs. Choosing the appropriate treatment for pregnant and
lactating patients is an extremely challenging task.
The management of pregnancy and lactation in patients
with rheumatic diseases in the use of biological DMDs should
be multidisciplinary, involving the patient and her partner,
the rheumatologist and the obstetrician, being taken into
account the risks and beneﬁts of these drugs, other therapeu-
tic options, the intensity of the inﬂammatory disease and the
underlying safety for the mother, fetus and neonate.225
In general, biological DMDs should be avoided during preg-
nancy and lactation, since according to the currently available
evidence, FDA does not describe any biological therapy as
provenly safe during human pregnancy. Anti-TNF drugs are
classiﬁed as B (animal studies with no fetal risk, with no con-
trolled human studies, or animal studies with risk that has
not been proven in humans in the ﬁrst trimester of gestation,
with no evidence of later risk), while RTX, ABAT and TOCI
are categorized as C (studies in animals have shown terato-
genic effects; and there are no controlled human studies, or no
studies available in humans and animals, these being consid-
ered substances that should be used only if potential beneﬁts
justify potential risks to the fetus).226
Transplacentary  transit
Children are protected from infectious diseases in their ﬁrst
months of life by maternal antibodies that cross the pla-
centa in the second half of pregnancy. The antibodies’ transfer
through the placenta begins in the second trimester, but
increases linearly until delivery. At the end of pregnancy, the
amount of maternal antibodies of IgG isotype is higher in the
fetus than in the mother herself. This same pattern remains,
when the IgG is an anti-TNF drug.225,227
There is evidence that a signiﬁcant amount of anti-TNF
cross the placenta, especially during the third trimester. Small
amounts of anti-TNF are detected in breast milk.228
There are no conclusive data on ABAT, TOCI and RTX cross-
ing the human placenta and their possible excretion in breast
milk.
As for RTX, by being an IgG antibody, the drug could cross
the placenta and interfere with fetal and neonatal B-cell
development. Moreover, its pharmacokinetic properties and
long-term effects would allow the hypothetical occurrence
of adverse effects, even in cases of exposure months before
conception.225 However, as we  shall see, in the few cases
described of occurrence of pregnancy in women treated with
RTX, no fetal or neonatal complications were observed, which,
due to the small number of cases, does not allow inferences.
Thus, RTX is also contraindicated in pregnancy.
Outcome  of  pregnancies  exposed  to  biological  DMARDs
In a recent SLR, Bogas and Leandro identiﬁed all publications
in humans with results on the fetus or newborn after exposure
to biological therapies during pregnancy. Sixty-ﬁve publica-
tions and 745 references on the subject were identiﬁed and
229evaluated.
Table 2 summarizes the outcome of pregnancies with expo-
sure to biological DMDs, considering each drug in isolation,
based on information currently available. 0 1 5;5 5(3):281–309
It is important to emphasize the following considerations
on pregnancies’ outcomes229:
1. Many women had active disease and were concomitantly
exposed to potentially teratogenic drugs such as MTX  and
leﬂunomide.
2. The exposure to biological DMDs can be divided into two
groups: (a) unplanned pregnancy – the exposure occurred
at the time of conception and during the ﬁrst trimester,
and in most cases the drug was discontinued as soon as
pregnancy was conﬁrmed; (b) pregnant women who were
intentionally treated, due to a refractory active disease.
3. There is great variation in the dose of the biological DMD
used, depending on the underlying disease.
4. The outcome of each pregnancy can be dependent on
several other factors, including the mother, the under-
lying disease, disease activity and the presence of
comorbidities,230 and such information was not present in
the majority of reports available
5. Overall, congenital abnormalities are described in 3–5%
of the live births, and some of them appear to be rel-
atively common, including the involvement of the CNS,
heart, limbs, and urinary system (with a prevalence of
more than 20 cases per 10,000 births).231 VACTREL is a
non-random association of birth defects which occurs
in 1.6 per 10,000 live births232 (V, vertebral defects,
a, anal atresia; C, cardiac abnormalities; T, tracheoe-
sophageal ﬁstula or atresia/tracheal stenosis; E, esophageal
atresia; R, renal or radial abnormalities; L, abnormal-
ities in pre-axial members). The possible association
between VACTREL and biologicals’ use (especially anti-
TNF drugs) has been raised, but currently this is being
questioned.225
6. The frequency of premature births varies from 5% to 13%
in developed countries.233 The risk of congenital anoma-
lies or prematurity appears to be greater in patients
with RA, compared to pregnant women without such
diagnosis.230
7. Absence of control groups not treated with biologicals in
most series and reports included in Bogas and Leandro’s
SRL229 may have occasioned a bias, but, in general, no spe-
ciﬁc pattern of congenital defect was observed in children
exposed to intrauterine biologicals.
In 2011 a review of 231 cases of pregnant women
exposed to RTX (the whole range of indications of drug use,
including those non-associated to rheumatic diseases) was
published.234 Of the 153 pregnancies with known outcomes, 90
resulted in live births. Twenty-two children were born prema-
turely, with one neonatal death in six weeks. Eleven neonates
exhibited hematologic changes, but not one had correspond-
ing infections. Although only a few congenital malformations
or neonatal infections were observed among exposed new-
borns, women should be advised to avoid pregnancy until 12
months after RTX exposure.Use  of  biologicals  during  lactation
The absorption of maternal antibodies through breast milk is
limited in humans, and the predominant Ig isotype in breast
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(3):281–309 299
Table 2 – Outcome of pregnancies with exposure to biological disease-modifying drugs (DMD), considering each drug on
an individual basis.
Drugs  Publications
available
Number  of
patients
exposed
during
pregnancy
Accidental
exposure
during  the
ﬁrst
trimester
Exposure  during
the  second  or third
trimester
Spontaneous
abortions
Elective
terminations
of  pregnancy
Live  births
without
complications
Preterm
deliveries
Related
malformations
Available
information  on
exposure  during
lactation
Adalimumab
(ADA)
11  (3  reports
and case
reports)
106  90%  10%  No
information
available
No
information
available
No  information
available
No
information
available
–  8 reports  of
malformations
– 1 VACTREL
– 1 undescended
testicle
– 1 microcephaly
– 1 ventricular
septal  defect
– 1 congenital  hip
dysplasia  with
inguinal  hernia
–  1 congenital
hypothyroidism
– 1 bicuspid  aortic
valve  with  agenesis
of the  corpus
callosum  (twin
pregnancy,  with
patent  ductus
arteriosus)
– 1 congenital
hydronephrosis
(twin  pregnancy,
suffered
miscarriage)
8
Certolizumab
(CERT)
2 (case  reports
–Crohn’s
disease)
2  1  1 No
information
available
No
information
available
2  (100%)  No
information
available
0  No  information
available
Etanercept
(ETN)
18 (3  reports,  5
case  series  and
case  reports)
199  70%  30%  1 case  of
trisomy  18
No
information
available
No  information
available
No
information
available
–  14  reports  of
malformations  or
other
complications
– 1 VACTREL
– 1 congenital
megacolon
– 1 atrial  septal
defect with  patent
ductus  arteriosus,
esotropia  and
inguinal  hernia
–  1 transverse
stomach,
epispadias  and
congenital  eye
defect  (twin
delivery, transverse
stomach)
– 1 ventricular
septal  defect  with
patent  foramen
ovale and  patent
ductus  arteriosus
– 1 ventricular
septal  defect  with
pulmonary
stenosis
–  1 pyloric  stenosis
– 1 cystic
adenomatous
malformation
– 1 hypospadias
with  inguinal
hernia
– 1 intestinal
volvulus
– 1 microcephaly
– 1 congenital
hypothyroidism
– 1 trisomy  21
–  1 a case  described
as congenital
abnormality  that
can  be  interpreted
as hereditary
adrenal
hyperplasia
No  information
available
Golimumab
(GOL)
No published
data  in
humans
(experimental
study  in
monkeys)
No
information
available
No
information
available
No  information
available
No
information
available
No
information
available
No  information
available
No
information
available
No  information
available
No  information
available
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Table 2 (Continued)
Drugs  Publications
available
Number  of
patients
exposed
during
pregnancy
Accidental
exposure
during the
ﬁrst
trimester
Exposure  during
the second  or  third
trimester
Spontaneous
abortions
Elective
terminations
of  pregnancy
Live  births
without
complications
Preterm
deliveries
Related
malformations
Available
information  on
exposure  during
lactation
Inﬂiximab
(IFX)
24  (4  reports,  3
series, case
reports)
156  70%  5–10% 8  neonates  with
congenital
malformations  and
other
complications
– 1 intestinal
malrotation
(concurrent  use  of
leﬂunomide)
– 1 tetralogy  of
Fallot
–  1 child  with
pulmonary  and
intracerebral
hemorrhage  –
death  at  24  weeks
–  1 death  on  the
third  day  of  life
(cause  unknown)
– 2 cases  of
respiratory  failure
(1  child  with
seizures)
– 2 cases  of  delayed
development  (1
hypothyroidism)
Abatecept
(ABAT)
Case reports  10  No
information
available
No  information
available
3  2 1  No
information
available
No  information
available
No  information
available
Rituximab
(RTX)
Case reports  16  3 8 1 15  No
information
available
No  information
available
No  information
available
Tocilizumab
(TOCI)
No
information in
literature
No
information
available
No
information
available
No  information
available
No
information
available
No
information
available
No  information
available
No
information
available
No  information
available
No  information
available
Modiﬁed from Refs. [226,230].
VACTREL, non-random association of birth defects; V, vertebral defects; A, anal atresia; C, cardiac abnormalities; T, tracheoesophageal ﬁstula
bnormor tracheal atresia/stenosis; E, esophageal atresia; R, renal or radial a
milk is IgA, which provides immunity to intestinal mucosa in
breastfeeding infants.227
Small amounts of IgG or other major Igs cross breast acini,
and thus cannot be found in the blood of breastfeeding infants
in signiﬁcant quantities. For this reason, it is expected that
the passage of anti-TNF drugs through breast milk be mini-
mal. There are few data from experimental (animal) or clinical
studies producing such information. There are some reported
cases of mothers that were treated with anti-TNF, and it does
not seem that this class of drug is transferred between the
mother and her baby through breast milk.225
There are no consistent data on the passage of other non-
anti-TNF biological drugs through breast milk.
Recommendations  for  the  use  of  biologicals  during
pregnancy  and  lactation
The information in the literature about the use of biologicals
during pregnancy and lactation in patients with rheumatic
diseases is still scarce, especially with regard to non-anti-TNF
drugs; we  emphasize that, in general, the use of such drugs
should be avoided during pre-conception, pregnancy and lac-
tation periods.
With respect to anti-TNF DMDs, based on information cur-
rently available and on the extrapolation of currently existing
guidelines on the use of anti-TNF therapy in patients with
inﬂammatory bowel disease,235 the recommendations listed
below are suggested.alities; L, abnormalities in pre-axial members.
Preconception  exposure
Considering that anti-TNF drugs hypothetically do not cross
the placental barrier in the ﬁrst trimester, it would be possible
to allow the use of anti-TNF until the moment of conception.
Exposure  during  pregnancy
Anti-TNF drugs should be discontinued during pregnancy. In
case of a very intense activity of the underlying disease, we
could argue in favor of an eventual prescription or reintro-
duction of one of these drugs during pregnancy – preferably,
if possible, with a dose reduction and a more  spaced period
between administrations, with its discontinuation eight to 10
weeks before the expected date of conﬁnement.
Exposure  during  lactation
Anti-TNF drugs should be avoided during lactation. However,
in case of intense disease activity, and considering that the
limited number of cases reported to date seems to indicate
that small amounts of anti-TNF drugs pass into breast milk,
the prescription of such drugs during lactation would be pos-
sible in those cases where the beneﬁt to the mother outweighs
the risk to her child.
In summary, the use of biological DMDs should be avoided
during pre-conception, pregnancy and lactation periods.
Exceptionally, in the case of an intense activity of the
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isease, and when the maternal beneﬁt outweighs the risk
o the fetus, and also in common agreement with the obste-
rician, the patient and her family, the eventual prescription
r reintroduction of an anti-TNF drug during pregnancy may
e considered – preferably, if possible, with a dose reduction
nd a more  spaced period between administrations, with its
iscontinuation eight to 10 weeks before the expected date
f conﬁnement. The prescription of anti-TNF during lacta-
ion may be possible in cases where the beneﬁt to the mother
utweighs the risk to her child.
inal  considerations  and  conclusions
he treatment of rheumatic diseases of immunoinﬂammatory
ature, especially RA and spondyloarthritides, has undergone
igniﬁcant change in recent years. The emphasis on early diag-
osis, the immediate introduction of DMDs, and in a rigorous
onitoring of therapeutic response, as well as the develop-
ent of immunobiological agents, have revolutionized the
ay these diseases are being treated. SBR has been devoted
o produce documents that guide the rheumatologist on the
iagnostic and therapeutic management of RA37,158,224,236–238
nd spondyloarthritides,12,239 including information on the
se of biological DMDs in these conditions.
Due to fears about the safety proﬁle, immunobiological
gents were initially reserved for advanced forms of the dis-
ase refractory to traditional medicines. Today, some 15 years
fter the beginning of their commercialization and with the
xperience gained in patients’ monitoring, their use is already
ndicated in less severe cases and even in selected cases, in
arlier stages of these diseases.
The safety of biological agents in the short term has been
ell established in pivotal studies on each of these products.
lthough involving difﬁcult to control patients, refractory to
everal DMDs, the inclusion criteria of these studies excluded
atients with systemic manifestations of the diseases and
ith relevant comorbidities. Register studies, on the other
and, assess the safety also in the medium and long term and
nclude patients more  similar to those in our daily practice.
o far, these drugs have been shown to be relatively safe. A
ew challenge arises with the use, in sequence and by the
ame patient, of different biological agents. Pharmacosurveil-
ance studies become even more  relevant in the long-term
valuation of these patients.
Experience shows that the most powerful tools may have
he most inﬂuential adverse consequences. This principle,
hich is valid also for clinical pharmacology, applies emphat-
cally to immunobiological drugs, due to the wide spectrum
f actions exercised in the intimacy of various immunologi-
al mechanisms. In fact, this review consistently showed the
iversity of adverse events associated with immunobiologi-
al therapy. With this warning notice, we  would emphasize
he importance of dedication and surveillance to the safety
spects of this class of drugs.
This review sought to provide a broad and balanced update
f clinical and experimental data accumulated in the last two
ecades of use of immunobiological drugs to patients with
utoimmune rheumatic diseases, with an emphasis in RA
nd spondyloarthritides. For chronological reasons, the largest 5;5 5(3):281–309 301
experience to date refers to immunobiologicals that antago-
nize TNF. Despite the relative safety of biological agents, we
must keep all our attention in the selection and monitoring of
patients with indications of these drugs.
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